Developing the Anti-Inflammatory Drugs of the Future
Celsus Therapeutics is a drug development company focusing on novel anti-inflammatory, first-in-class synthetic drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs). Celsus’s proprietary drug technology platform is unique and potentially offers an answer to an urgent unmet need: the lack of satisfactory alternatives to corticosteroids in the treatment of a multitude of inflammatory diseases. The company has assembled an experienced team that shares its vision and is committed to making it a success.
Innovative Technology
Celsus is targeting four major inflammatory disease areas: Dermatology (contact dermatitis) Respiratory (allergic rhinitis and cystic fibrosis) Gastro-intestinal...
Pipeline
• MRX6: topical cream for eczema
• MRX5: oral drug for IBD
• CFX1: pulmonary drug for CF
• OPT1: eye drops for ocular inflammation.
Press Releases
June 17, 2014 Celsus Therapeutics Plc Receives Approval from the Ministry of Health of Israel For Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients